Navigation Links
a New Pill Can eliminate menstruation

Scientists now will make women more empowered. They have now developed a new contraceptive pill that promises to eliminate menstruation completely. The pill developed by New Jersey-based Wyeth and called 'Anya', may help women to avoid unplanned// pregnancies and the inconvenience of periods.

Critics have warned that oral contraceptives raise the risk of blood clots and breast cancer. They said continuous exposure to hormones might increase these risks and make it harder to spot potential health problems.

However, the manufacturer said the pill that has to be taken 365 days a year without a break was given to about 2,000 women for a study and just six had serious side effects such as prolonged bleeding or blood clots.

Like any other pill, 'Anya' avoids pregnancy by stopping ovulation, preventing eggs being released by copying the hormonal state of pregnancy. Numerous studies show this does not harm a woman's fertility because ovulation resumes when she stops taking the pill, it said.

A woman's body normally prepares for pregnancy every month by building up the lining of the womb. However, if the egg is unfertilised, the lining is shed in the process of menstruation. Because the pill stops ovulation, the womb lining does not build up in the normal way.

The 'withdrawal bleed' a woman gets when she takes a seven-day break from other contraceptive pills is in fact triggered simply by the sudden drop in hormones.

However, in the case of the new pill, there is no trigger for this process as there is no break and the lining remains without causing any problem to the woman.

Wyeth hopes to make the pill available for sale in the US next year and across the EU later. Analysts believe it could generate 170 million pounds annually in worldwide sales.

(Source: IANS)
'"/>




Page: 1

Related medicine news :

1. Jumping genes eliminate sections of DNA
2. HIV discrimination in workplace should be eliminated
3. Asthma linked to irregular menstruation
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... Olathe, KS (PRWEB) , ... April 28, 2017 ... ... system have typically been previously exposed to more adverse experiences than children in ... have experienced trauma such as abuse, neglect or other family challenges. While no ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... the Creator responds to and which He does not. Yisrayl says with so many ... is the true name, but he says with a little Scripture, backed with a lot ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that ... his presence to an educational purpose as the host of the “Informed” series. The ... In a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: